ClinicalTrials.gg
RecruitingNCT05916950THORUpdated Nov 5, 2026

The THOR IDE Study

An interventional study of Thor laser atherectomy in Peripheral Artery Disease, Peripheral Artery Stenosis and Peripheral Artery Calcification, sponsored by Philips Clinical & Medical Affairs Global. Recruiting at 29 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Philips Clinical & Medical Affairs Global (part of Philips) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Updated Nov 5, 2026Site recruiting status changedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
155
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Peripheral Arterial Disease by Philips — 1 open to participants now, 1 under way, none of them phase 3. Peripheral Arterial Disease · Philips.

Planned enrollment
9th of 18
155 · median 142
Started
2024
the only one that year
No phase
13 of 24
1 open now
Registered
24th of 24
by date

Among the 24 studies in Peripheral Arterial Disease by Philips, this one is the 9th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2024, is one of 13 with no phase, and was the 24th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

1 of the 24 studies in Peripheral Arterial Disease by Philips is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Peripheral Arterial Disease by Philips, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test the Thor system in adult (≥ 18 year old) patients with de novo (new, never treated) calcified lesions in infrainguinal (leg) arteries (peripheral artery disease or PAD).

The main question[s] it aims to answer are:

  • Is the Thor system safe in treating these lesions
  • Does the Thor system work to treat these lesions

Participants will:

  • Receive treatment with the Thor system
  • Have follow-up visits at Discharge, 30 days, 6 months, and 12 months
Read the detailed description

Up to 30 sites in the U.S. will be selected to do this study.

Patients with pain in their legs when walking and/or resting that is due to lack of blood flow to their legs may be able to join the study. To join the study patients must also have blockages in their leg arteries that meet the study criteria.

Before the Thor procedure, patients will have a screening visit that includes a review of their medical records, questions about their medical history and medications taken for blood thinning or circulation, a physical examination of their legs, a test to check the blood flow in their legs (by checking arm and leg blood pressures), blood tests, and a pregnancy test if they are a female able to have children. Patients will also answer questions about any trouble they have had with walking in the last week and their overall quality of life.

All patients in the study will have treatment with the Thor system. There is no "control group" (a group of patients that receives only standard treatment or receives no treatment at all) in this study. During the procedure, the doctor will take x-ray pictures of the leg arteries. They may also use other treatments such as angioplasty balloons, drug-coated balloons, stents, and filters that collect blood clots, if needed.

Patients treated with the Thor system will be watched until they are ready to go home or up to 24 hours after the procedure if they do not go home right away. Before they go home they will have a test to check the blood flow to their legs (by checking arm and leg blood pressures) and be checked for any adverse events.

Patients will return for visits at 30 days, 6 months, and 12 months after the Thor procedure. At these visits patients will be asked questions about their medical history and medications taken for blood thinning or circulation, have a physical examination of their legs, have a test to check the blood flow in their treated leg (by checking arm and leg blood pressures), have an ultrasound of their treated leg, and be checked for any adverse events. Patients will also answer questions about any trouble they have had with walking in the last week and their overall quality of life.

It will take up to 24 months (2 years) to enroll all of the patients in the study. Patients who join the study will be in the study for about 12 months (1 year) and will have all of the visits with their doctor that they would normally have for their PAD.

03

Conditions studied

  • Peripheral Artery Disease
  • Peripheral Artery Stenosis
  • Peripheral Artery Calcification
  • PAD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient age is ≥18 years
  • Patient agrees to participate and to comply with the protocol by signing an IRB approved patient consent form
  • Patient is able to walk unassisted or with non-motorized assistive devices
  • Patient has PAD with documented Rutherford Class 2-4 of the target limb
  • Anticipated >12 months, in the opinion of the investigator at the time of enrollment.

Angiographic Inclusion Criteria:

  • Patient has de novo atherosclerotic disease of the native SFA and/or the popliteal arteries
  • Target lesion has ≥70% diameter stenosis by investigator via visual assessment
  • Target lesion length ≤150mm. Total treatment zone may not exceed 150mm, and may include one or more lesions.
  • Chronic total occlusion lesion length is \<100mm of the total ≤150mm target lesion
  • Minimum reference vessel diameter (RVD) 4.0mm by visual estimate
  • Target lesion crossed and intraluminal guidewire placement confirmed; successful crossing defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations
  • At least one patent tibial vessel (defined as \<50% stenosis) with runoff to the foot
  • Target lesion has moderate to severe calcification graded using the Peripheral Academic Research Consortium (PARC) criteria

Exclusion criteria

Exclusion Criteria:

  • Patient has active infection requiring antibiotic therapy
  • Stenting planned within the target lesion
  • Known positive for COVID-19 within the last 2 weeks and actively symptomatic
  • Pregnant (positive pregnancy test) or currently breast feeding
  • Evidence of Acute Limb Ischemia in the target limb within 7 days prior to procedure
  • Cerebrovascular accident (CVA) \<60 days prior to procedure
  • Myocardial infarction \<60 days prior to procedure
  • History of unstable coronary artery disease or other uncontrollable comorbidity resulting in hospitalization within the last 60 days prior to baseline screening
  • Known to aspirin, or antiplatelet/anti-coagulant therapies required for procedure/follow-up
  • Known allergy to contrast media that cannot adequately be premedicated prior to study procedure
  • History of Thrombophilia, Heparin-induced Thrombocytopenia (HIT), or Heparin-induced Thrombotic Thrombocytopenia Syndrome (HITTS)
  • Serum creatinine ≥2.5mg/dL (unless dialysis-dependent) tested within 30 days prior to procedure
  • Planned lower limb major amputation (above the ankle)
  • Other surgical or endovascular procedure in the target limb that occurred within 14 days prior to index procedure or is planned on target limb for within 30 days following index procedure, with the exception of diagnostic angiography
  • Currently participating in any device or drug clinical trial that, in the opinion of the investigator, will interfere with the conduct of the current study
  • The use of specialty balloons, re-entry or additional atherectomy devices is required for treatment of the target lesion.

Angiographic Exclusion Criteria:

  • Subject has significant stenosis (>50% stenosis) or occlusion of inflow tract before target treatment zone (e.g. iliac or common femoral) not successfully treated.
  • Subject requires treatment of a peripheral lesion on the ipsilateral limb distal to the target site at the time of the index procedure.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
155 participants (estimated)

Study arms

  • Experimental
    Thor Treatment

    Treatment with the Thor system

    Device: Thor laser atherectomy

Interventions

  • DeviceThor laser atherectomy

    Treatment of de novo calcified lesions with laser atherectomy and calcium modification using the Thor system

    Also known as: Thor calcium modification

06

What researchers measure

Primary outcomes

  1. Freedom from Major Adverse Events (MAEs)

    Defined as freedom from MAEs including all-cause mortality, clinically driven target lesion revascularization (CD-TLR), unplanned target limb major amputation, perforations, flow-limiting dissections, and symptomatic distal embolizations that require an intervention to resolve

    Time frame: 30 Days

  2. Procedural Success

    Defined as residual diameter stenosis ≤50% at the end of the procedure as determined by angiographic core lab

    Time frame: At completion of the procedure

Secondary outcomes

  1. Target lesion patency, 30 days

    Defined as freedom from CD-TLR and freedom from ≥50% restenosis as determined by duplex ultrasound (DUS) or angiogram

    Time frame: 30 days

  2. Target lesion patency, 6 months

    Defined as freedom from CD-TLR and freedom from ≥50% restenosis as determined by duplex ultrasound (DUS) or angiogram

    Time frame: 6 months

  3. Target lesion patency, 12 months

    Defined as freedom from CD-TLR and freedom from ≥50% restenosis as determined by duplex ultrasound (DUS) or angiogram

    Time frame: 12 months

  4. Clinically-driven target lesion revascularization

    Defined as repeat revascularization procedure of the target lesion if PSVR is ≥2.5 by DUS or if angiography shows a percent diameter stenosis \>50% and there are worsening clinical symptoms, worsening Rutherford Clinical Category or ABI that is clearly referable to the target lesion.

    Time frame: Through 12 months

  5. Technical success

    Defined as the ability to deliver the Thor system and achieve residual diameter stenosis ≤50% after treatment with Thor and prior to adjunctive PTA, as confirmed by independent core laboratory assessments of angiographic images

    Time frame: Peri-procedural

  6. Frequency of peri-procedural adverse events

    Defined as frequency of adverse events related to the investigational device (Thor system)

    Time frame: Within 24 hours of the procedure

  7. Adjunctive devices used with the Thor system

    Defined as the use of other devices including angioplasty balloons, drug coated balloons, bailout stents, embolic filters

    Time frame: Peri-procedural

  8. Target Limb Ankle-Brachial Index (ABI) change, Discharge

    Defined as the change in blood pressure in the upper limb (arm) and lower limb (leg or toes) at discharge compared to the baseline (Screening) value

    Time frame: Discharge or up to 24 hours after the procedure

  9. Target Limb Ankle-Brachial Index (ABI) change, 30 days

    Defined as the change in blood pressure in the upper limb (arm) and lower limb (leg or toes) at 30 days compared to the baseline (Screening) value

    Time frame: 30 days

  10. Target Limb Ankle-Brachial Index (ABI) change, 6 months

    Defined as the change in blood pressure in the upper limb (arm) and lower limb (leg or toes) at 6 months compared to the baseline (Screening) value

    Time frame: 6 months

  11. Target Limb Ankle-Brachial Index (ABI) change, 12 months

    Defined as the change in blood pressure in the upper limb (arm) and lower limb (leg or toes) at 12 months compared to the baseline (Screening) value

    Time frame: 12 months

  12. Rutherford Classification change, 30 days

    Defined as the change in Rutherford classification at 30 days compared to the baseline (Screening) value. Rutherford Classification is a staging system to describe reduced blood flow in the lower limb. Rutherford Classifications values range from the least severe (asymptomatic) which is scored a 0 to the most severe (ulceration or gangrene) which is scored a 6.

    Time frame: 30 days

  13. Rutherford Classification change, 6 months

    Defined as the change in Rutherford classification at 6 months compared to the baseline (Screening) value. Rutherford Classification is a staging system to describe reduced blood flow in the lower limb. Rutherford Classifications values range from the least severe (asymptomatic) which is scored a 0 to the most severe (ulceration or gangrene) which is scored a 6.

    Time frame: 6 months

  14. Rutherford Classification change, 12 months

    Defined as the change in Rutherford classification at 12 months compared to the baseline (Screening) value. Rutherford Classification is a staging system to describe reduced blood flow in the lower limb. Rutherford Classifications values range from the least severe (asymptomatic) which is scored a 0 to the most severe (ulceration or gangrene) which is scored a 6.

    Time frame: 12 months

  15. Freedom from Major Adverse Events (MAEs)

    Defined as freedom from MAEs including all-cause mortality, clinically driven target lesion revascularization (CD-TLR), unplanned target limb major amputation, and perforations, flow-limiting dissections, and symptomatic distal embolizations that require an intervention to resolve

    Time frame: Through 12 months

  16. Change in Short Form Health Survey (SF-36) score, 30 days

    Defined as the change in SF-36 score at 30 days compared to the baseline (Screening) value. The SF-36 is a patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

    Time frame: 30 days

  17. Change in Short Form Health Survey (SF-36) score, 6 months

    Defined as the change in SF-36 score at 6 months compared to the baseline (Screening) value. The SF-36 is a patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

    Time frame: 6 months

  18. Change in Short Form Health Survey (SF-36) score, 12 months

    Defined as the change in SF-36 score at 12 months compared to the baseline (Screening) value. The SF-36 is a patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

    Time frame: 12 months

  19. Change in Walking Impairment Questionnaire (WIQ) score, 30 days

    Defined as the change in WIQ score at 30 days compared to the baseline (Screening) value. The WIQ measures self-reported walking impairment, walking distance, walking speed, and stair-climbing ability. In the WIQ there are 21 questions to rate the degree of difficulty with the walking and stair climbing elements. The response for each question is on a 0 to 4 scale, where 0 represents the inability to walk or climb stairs, and 4 represents no difficulty.

    Time frame: 30 days

  20. Change in Walking Impairment Questionnaire (WIQ) score, 6 months

    Defined as the change in WIQ score at 6 months compared to the baseline (Screening) value. The WIQ measures self-reported walking impairment, walking distance, walking speed, and stair-climbing ability. In the WIQ there are 21 questions to rate the degree of difficulty with the walking and stair climbing elements. The response for each question is on a 0 to 4 scale, where 0 represents the inability to walk or climb stairs, and 4 represents no difficulty.

    Time frame: 6 months

  21. Change in Walking Impairment Questionnaire (WIQ) score, 12 months

    Defined as the change in WIQ score at 12 months compared to the baseline (Screening) value. The WIQ measures self-reported walking impairment, walking distance, walking speed, and stair-climbing ability. In the WIQ there are 21 questions to rate the degree of difficulty with the walking and stair climbing elements. The response for each question is on a 0 to 4 scale, where 0 represents the inability to walk or climb stairs, and 4 represents no difficulty.

    Time frame: 12 months

07

Study locations

27 of 29 sites recruiting
  • St. Helena Hospital
    St. Helena, California 94574, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Rocky Mountain Regional VA Medical Center
    Aurora, Colorado 80045, United States
    Recruiting
  • Manatee Memorial Hospital
    Bradenton, Florida 34205, United States
    Recruiting
  • Tallahassee Research Institute
    Tallahassee, Florida 32308, United States
    Recruiting
  • Guardian Research Organization
    Winter Park, Florida 32792, United States
    Recruiting
    • Kathleen Doyle · Contactkdoyle@guardian-research.com · 407-630-9997
    • Tiffany King · Contact
    • Ashish Gupta, MD · Principal investigator
    • Sandeep Bajaj · Sub investigator
  • Vascular Institute of the Midwest
    Davenport, Iowa 52807, United States
    Recruiting
  • Cardiovascular Institute of the South
    Houma, Louisiana 70360, United States
    Recruiting
    • Darla Patrick · Contactdarla.patrick@cardio.com · (985) 873-5684
    • Deanna Benoit · Contactdeanna.benoit@cardio.com · (985) 873-5613
    • Craig Walker, MD · Principal investigator
    • Pradeep Nair, MD · Sub investigator
    • Matthew Finn, MD · Sub investigator
    • McCall Walker, MD · Sub investigator
  • Cardiovascular Institute of the South
    Lafayette, Louisiana 70503, United States
    Recruiting
    • Ariel Quebedeaux · ContactAriel.Quebedeaux@cardio.com · (337) 289-8429
    • Ankur Lodha, MD · Principal investigator
    • Amit Amin, MD · Sub investigator
    • David Tadin, MD · Sub investigator
  • The Vascular Care Group
    Portland, Maine 04106, United States
    Recruiting
    • Jennifer Legrand · Contactjlegrand@vascularcaregrp.com · 978-534-3399
    • Nathan Aranson, MD · Principal investigator
    • Christopher Kwolek, MD · Sub investigator
    • Daniel Gorin, MD · Sub investigator
    • Todd Lancaster, MD · Sub investigator
  • Southcoast Hospitals/Charlton Memorial Hospital
    Fall River, Massachusetts 02720, United States
    Recruiting
    • Debra Benevides · Contactbenevidesd@southcoast.org · 508-973-7775
    • Richard Pin, MD · Principal investigator
    • Mark Perry, MD · Sub investigator
    • Brandon Sumpio, MD · Sub investigator
  • Vascular Breakthroughs
    Leominster, Massachusetts 04153, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Henry Ford St John Hospital
    Detroit, Michigan 22201, United States
    Recruiting
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
    Recruiting
    • Kate Ryan · Contactkryan10@hfhs.org · 313-916-1057
    • Melanee Schimmel · Contactmschimm2@hfhs.org
    • Herbert Aronow, MD · Sub investigator
    • Pedro Villablanca, MD · Sub investigator
    • Gerald Koenig, MD · Sub investigator
    • Vikas Aggarwal, MD · Sub investigator
    • Mohammad Alqarqaz, MD · Sub investigator
    • Khaldoon Alaswad, MD · Sub investigator
    • Kyle Markel, MD · Principal investigator
  • Deborah Heart and Lung Center
    Browns Mills, New Jersey 08015, United States
    Recruiting
  • Heart and Vascular Institute of Central Jersey
    New Brunswick, New Jersey 08901, United States
    Recruiting
  • Atlantic Medical Imaging of New jersey
    Vineland, New Jersey 08360, United States
    Recruiting
    • Melisa Rivera · Contactmrivera@aminj.com · 856.362.6056
    • Lenice Valdes · Contactlvaldes@aminj.com
    • Micah Watts, MD · Principal investigator
    • Nicholas Petruzzi, MD · Sub investigator
    • Ramkrishna Patel, MD · Sub investigator
  • Mount Sinai Hospital
    New York, New York 10029, United States
    Recruiting
  • New York Presbyterian Hospital/Columbia University Irving Medical Center
    New York, New York 10029, United States
    Recruiting
    • Hana Tomizawa · Contactht2740@cumc.columbia.edu · (212) 342-4102
    • Claudia Musat · Contactcm2065@cumc.columbia.edu
    • Virendra Patel, MD · Principal investigator
    • Thomas O'Donnell, MD · Sub investigator
    • Nicholas Morrissey · Sub investigator
    • Danielle Bajakian · Sub investigator
  • Vascular Solutions of North Carolina
    Cary, North Carolina 27518, United States
    Recruiting
  • Premier Cardiovascular Institute
    Fairborn, Ohio 45324, United States
    Recruiting
  • Ascension St. John
    Bartlesville, Oklahoma 74006, United States
    Recruiting
    • Mary Harris · Contactmary.harris5@ascension.org
    • · Contact918.332.3616
    • Anderson Merhle, MD · Principal investigator
    • Michael Megaly, MD · Sub investigator
  • UPMC
    Mechanicsburg, Pennsylvania 17050, United States
    Recruiting
    • Laura Wells · Contactwellsla2@upmc.edu · 717- 920 4402
    • Gretchen Meise · Contactmeisegc@upmc.edu · 717.920.4464
    • William Bachinsky, Dr · Principal investigator
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Alice Chen · ContactAlice.Chen1@Pennmedicine.upenn.edu · 215-459-4478
    • Elizabeth Genovese, MD · Principal investigator
    • Shang Loh, MD · Sub investigator
    • Alexander Fairman, MD · Sub investigator
    • Douglas Troutman, MD · Sub investigator
  • Lankenau Institute for Medical Research
    Wynnewood, Pennsylvania 19096, United States
    Recruiting
    • Lucy Delp · Contactdelpl@mlhs.org · 484.476.8512
    • Lynn Sher · ContactSherL@mlhs.org · 484.476.8581
    • Antonis Pratsos, MD · Principal investigator
    • Manju Jayanna, MD · Sub investigator
    • Sarang Mangalmurti, MD · Sub investigator
  • The Miriam Hospital
    Providence, Rhode Island 02905, United States
    Recruiting
    • Lina Felix · Contactlfelix@lifespan.org · 407-793-4105
    • Peter Soukas, MD · Principal investigator
    • Pieter de Klerk, MD · Sub investigator
  • Vascular Institute of Chattanooga
    Chattanooga, Tennessee 37421, United States
    Recruiting
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
    Recruiting
  • Baylor, Scott & White, The Heart Hospital
    Plano, Texas 75093, United States
    Recruiting
  • Sentara Health Research Center
    Norfolk, Virginia 23507, United States
    Recruiting
    • Sarah Keith · ContactSkescoba@sentara.com
    • David Dexter, MD · Principal investigator
    • Animesh Rathore, MD · Sub investigator
    • Priyam Vyas, MD · Sub investigator
08

References and documents

Publications

  • Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group; Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J, Clement D, Creager M, Jaff M, Mohler E 3rd, Rutherford RB, Sheehan P, Sillesen H, Rosenfield K. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1-75. doi: 10.1016/j.ejvs.2006.09.024. Epub 2006 Nov 29. No abstract available. PubMed 17140820 ↗
  • Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006 Mar 21;113(11):e463-654. doi: 10.1161/CIRCULATIONAHA.106.174526. No abstract available. PubMed 16549646 ↗
  • Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001 Sep 19;286(11):1317-24. doi: 10.1001/jama.286.11.1317. PubMed 11560536 ↗
  • Mueller T, Hinterreiter F, Poelz W, Haltmayer M, Dieplinger B. Mortality rates at 10 years are higher in diabetic than in non-diabetic patients with chronic lower extremity peripheral arterial disease. Vasc Med. 2016 Oct;21(5):445-452. doi: 10.1177/1358863X16643603. Epub 2016 Apr 11. PubMed 27067137 ↗
  • Caro J, Migliaccio-Walle K, Ishak KJ, Proskorovsky I. The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. BMC Cardiovasc Disord. 2005 Jun 22;5:14. doi: 10.1186/1471-2261-5-14. PubMed 15972099 ↗
  • Dieter RS, Chu WW, Pacanowski JP Jr, McBride PE, Tanke TE. The significance of lower extremity peripheral arterial disease. Clin Cardiol. 2002 Jan;25(1):3-10. doi: 10.1002/clc.4950250103. PubMed 11808837 ↗
  • Guez D, Hansberry DR, Gonsalves CF, Eschelman DJ, Parker L, Rao VM, Levin DC. Recent Trends in Endovascular and Surgical Treatment of Peripheral Arterial Disease in the Medicare Population. AJR Am J Roentgenol. 2020 May;214(5):962-966. doi: 10.2214/AJR.19.21967. Epub 2020 Feb 25. PubMed 32097027 ↗
  • Rocha-Singh KJ, Jaff MR, Crabtree TR, Bloch DA, Ansel G; VIVA Physicians, Inc. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 2007 May 1;69(6):910-9. doi: 10.1002/ccd.21104. PubMed 17377972 ↗
  • Minar E, Pokrajac B, Maca T, Ahmadi R, Fellner C, Mittlbock M, Seitz W, Wolfram R, Potter R. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty : results of a prospective randomized study. Circulation. 2000 Nov 28;102(22):2694-9. doi: 10.1161/01.cir.102.22.2694. PubMed 11094034 ↗
  • van der Zaag ES, Legemate DA, Prins MH, Reekers JA, Jacobs MJ. Angioplasty or bypass for superficial femoral artery disease? A randomised controlled trial. Eur J Vasc Endovasc Surg. 2004 Aug;28(2):132-7. doi: 10.1016/j.ejvs.2004.04.003. PubMed 15234692 ↗
  • Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, Schlager O, Cejna M, Lammer J, Minar E. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006 May 4;354(18):1879-88. doi: 10.1056/NEJMoa051303. PubMed 16672699 ↗
  • Pokrajac B, Potter R, Wolfram RM, Budinsky AC, Kirisits C, Lileg B, Mendel H, Sabeti S, Schmid R, Minar E. Endovascular brachytherapy prevents restenosis after femoropopliteal angioplasty: results of the Vienna-3 randomised multicenter study. Radiother Oncol. 2005 Jan;74(1):3-9. doi: 10.1016/j.radonc.2004.08.015. PubMed 15683661 ↗
  • Krankenberg H, Schluter M, Steinkamp HJ, Burgelin K, Scheinert D, Schulte KL, Minar E, Peeters P, Bosiers M, Tepe G, Reimers B, Mahler F, Tubler T, Zeller T. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007 Jul 17;116(3):285-92. doi: 10.1161/CIRCULATIONAHA.107.689141. Epub 2007 Jun 25. PubMed 17592075 ↗
  • Sabeti S, Schillinger M, Amighi J, Sherif C, Mlekusch W, Ahmadi R, Minar E. Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: propensity score-adjusted analysis. Radiology. 2004 Aug;232(2):516-21. doi: 10.1148/radiol.2322031345. PubMed 15286322 ↗
  • Ferreira M, Lanziotti L, Monteiro M, Abuhadba G, Capotorto LF, Nolte L, Fearnot N. Superficial femoral artery recanalization with self-expanding nitinol stents: long-term follow-up results. Eur J Vasc Endovasc Surg. 2007 Dec;34(6):702-8. doi: 10.1016/j.ejvs.2007.07.025. Epub 2007 Oct 24. PubMed 17920306 ↗
  • Dosluoglu HH, Cherr GS, Lall P, Harris LM, Dryjski ML. Stenting vs above knee polytetrafluoroethylene bypass for TransAtlantic Inter-Society Consensus-II C and D superficial femoral artery disease. J Vasc Surg. 2008 Nov;48(5):1166-74. doi: 10.1016/j.jvs.2008.06.006. Epub 2008 Aug 9. PubMed 18692357 ↗
  • Dearing DD, Patel KR, Compoginis JM, Kamel MA, Weaver FA, Katz SG. Primary stenting of the superficial femoral and popliteal artery. J Vasc Surg. 2009 Sep;50(3):542-7. doi: 10.1016/j.jvs.2009.04.019. Epub 2009 Jun 21. PubMed 19540706 ↗
  • Zeller T, Tiefenbacher C, Steinkamp HJ, Langhoff R, Wittenberg G, Schluter M, Buergelin K, Rastan A, Krumsdorf U, Sixt S, Schulte CL, Tubler T, Krankenberg H. Nitinol stent implantation in TASC A and B superficial femoral artery lesions: the Femoral Artery Conformexx Trial (FACT). J Endovasc Ther. 2008 Aug;15(4):390-8. doi: 10.1583/08-2461.1. PubMed 18729564 ↗
  • Schlager O, Dick P, Sabeti S, Amighi J, Mlekusch W, Minar E, Schillinger M. Long-segment SFA stenting--the dark sides: in-stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther. 2005 Dec;12(6):676-84. doi: 10.1583/05-1672.1. PubMed 16363897 ↗
  • Inoue S, Koyama H, Miyata T, Shigematsu H. Pathogenetic heterogeneity of in-stent lesion formation in human peripheral arterial disease. J Vasc Surg. 2002 Apr;35(4):672-8. doi: 10.1067/mva.2002.122021. PubMed 11932661 ↗
  • Soor GS, Vukin I, Leong SW, Oreopoulos G, Butany J. Peripheral vascular disease: who gets it and why? A histomorphological analysis of 261 arterial segments from 58 cases. Pathology. 2008 Jun;40(4):385-91. doi: 10.1080/00313020802036764. PubMed 18446629 ↗
  • Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1996 Aug;16(8):978-83. doi: 10.1161/01.atv.16.8.978. PubMed 8696962 ↗
  • Shanahan CM, Cary NR, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME. Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation. 1999 Nov 23;100(21):2168-76. doi: 10.1161/01.cir.100.21.2168. PubMed 10571976 ↗
  • Thompson B, Towler DA. Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol. 2012 Sep;8(9):529-43. doi: 10.1038/nrendo.2012.36. Epub 2012 Apr 3. PubMed 22473330 ↗
  • Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014 May 1;83(6):E212-20. doi: 10.1002/ccd.25387. Epub 2014 Feb 10. PubMed 24402839 ↗
  • Lanzer P, Boehm M, Sorribas V, Thiriet M, Janzen J, Zeller T, St Hilaire C, Shanahan C. Medial vascular calcification revisited: review and perspectives. Eur Heart J. 2014 Jun 14;35(23):1515-25. doi: 10.1093/eurheartj/ehu163. Epub 2014 Apr 16. PubMed 24740885 ↗
  • Isner JM, Rosenfield K. Redefining the treatment of peripheral artery disease. Role of percutaneous revascularization. Circulation. 1993 Oct;88(4 Pt 1):1534-57. doi: 10.1161/01.cir.88.4.1534. No abstract available. PubMed 8403302 ↗
  • Schramm KM, DeWitt PE, Dybul S, Rochon PJ, Patel P, Hieb RA, Rogers RK, Ryu RK, Wolhauer M, Hong K, Trivedi PS. Recent Trends in Clinical Setting and Provider Specialty for Endovascular Peripheral Artery Disease Interventions for the Medicare Population. J Vasc Interv Radiol. 2020 Apr;31(4):614-621.e2. doi: 10.1016/j.jvir.2019.10.025. Epub 2020 Feb 29. PubMed 32127322 ↗
  • Walker KL, Nolan BW, Columbo JA, Rzucidlo EM, Goodney PP, Walsh DB, Atkinson BJ, Powell RJ. Lesion complexity drives the cost of superficial femoral artery endovascular interventions. J Vasc Surg. 2015 Oct;62(4):998-1002. doi: 10.1016/j.jvs.2015.04.450. Epub 2015 Jul 21. PubMed 26206581 ↗
  • Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation. 1991 Feb;83(2 Suppl):I70-80. PubMed 1825050 ↗
  • Herten M, Torsello GB, Schonefeld E, Stahlhoff S. Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease. Vasc Health Risk Manag. 2016 Aug 29;12:341-56. doi: 10.2147/VHRM.S81122. eCollection 2016. PubMed 27621646 ↗
  • Brodmann M, Werner M, Holden A, Tepe G, Scheinert D, Schwindt A, Wolf F, Jaff M, Lansky A, Zeller T. Primary outcomes and mechanism of action of intravascular lithotripsy in calcified, femoropopliteal lesions: Results of Disrupt PAD II. Catheter Cardiovasc Interv. 2019 Feb 1;93(2):335-342. doi: 10.1002/ccd.27943. Epub 2018 Nov 25. PubMed 30474206 ↗
  • Brodmann M, Werner M, Brinton TJ, Illindala U, Lansky A, Jaff MR, Holden A. Safety and Performance of Lithoplasty for Treatment of Calcified Peripheral Artery Lesions. J Am Coll Cardiol. 2017 Aug 15;70(7):908-910. doi: 10.1016/j.jacc.2017.06.022. No abstract available. PubMed 28797363 ↗
  • Adams G, Soukas PA, Mehrle A, Bertolet B, Armstrong EJ. Intravascular Lithotripsy for Treatment of Calcified Infrapopliteal Lesions: Results from the Disrupt PAD III Observational Study. J Endovasc Ther. 2022 Feb;29(1):76-83. doi: 10.1177/15266028211032953. Epub 2021 Aug 12. PubMed 34380334 ↗
  • Tepe G, Brodmann M, Werner M, Bachinsky W, Holden A, Zeller T, Mangalmurti S, Nolte-Ernsting C, Bertolet B, Scheinert D, Gray WA; Disrupt PAD III Investigators. Intravascular Lithotripsy for Peripheral Artery Calcification: 30-Day Outcomes From the Randomized Disrupt PAD III Trial. JACC Cardiovasc Interv. 2021 Jun 28;14(12):1352-1361. doi: 10.1016/j.jcin.2021.04.010. PubMed 34167675 ↗
  • Stavroulakis K, Bisdas T, Torsello G, Tsilimparis N, Damerau S, Argyriou A. Intravascular Lithotripsy and Drug-Coated Balloon Angioplasty for Severely Calcified Femoropopliteal Arterial Disease. J Endovasc Ther. 2023 Feb;30(1):106-113. doi: 10.1177/15266028221075563. Epub 2022 Feb 7. PubMed 35130782 ↗
  • Radaideh Q, Shammas NW, Shammas WJ, Shammas GA. Shockwave Lithoplasty in Combination With Atherectomy in Treating Severe Calcified Femoropopliteal and Iliac Artery Disease: A Single-Center Experience. Cardiovasc Revasc Med. 2021 Jan;22:66-70. doi: 10.1016/j.carrev.2020.06.015. Epub 2020 Jun 11. PubMed 32563711 ↗
  • Patel MR, Conte MS, Cutlip DE, Dib N, Geraghty P, Gray W, Hiatt WR, Ho M, Ikeda K, Ikeno F, Jaff MR, Jones WS, Kawahara M, Lookstein RA, Mehran R, Misra S, Norgren L, Olin JW, Povsic TJ, Rosenfield K, Rundback J, Shamoun F, Tcheng J, Tsai TT, Suzuki Y, Vranckx P, Wiechmann BN, White CJ, Yokoi H, Krucoff MW. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol. 2015 Mar 10;65(9):931-41. doi: 10.1016/j.jacc.2014.12.036. PubMed 25744011 ↗
  • Dattilo R, Himmelstein SI, Cuff RF. The COMPLIANCE 360 degrees Trial: a randomized, prospective, multicenter, pilot study comparing acute and long-term results of orbital atherectomy to balloon angioplasty for calcified femoropopliteal disease. J Invasive Cardiol. 2014 Aug;26(8):355-60. PubMed 25091093 ↗
  • Shammas NW, Chandra P, Brodmann M, Weinstock B, Sedillo G, Cawich I, Micari A, Lee A, Metzger C, Palena LM, Rundback J; EX-PAD-03 Investigators. Acute and 30-Day Safety and Effectiveness Evaluation of Eximo Medical's B-Laser, a Novel Atherectomy Device, in Subjects Affected With Infrainguinal Peripheral Arterial Disease: Results of the EX-PAD-03 Trial. Cardiovasc Revasc Med. 2020 Jan;21(1):86-92. doi: 10.1016/j.carrev.2018.11.022. Epub 2018 Nov 29. PubMed 30559030 ↗
  • Yamamoto Y, Kawarada O, Ando H, Anzai H, Zen K, Tamura K, Tsukahara K, Tsubakimoto Y, Toma M, Nakamura S, Nakamura H, Hozawa K, Yokoi Y, Yasuda S. Effects of high-speed rotational atherectomy in peripheral artery disease patients with calcified lesions: a retrospective multicenter registry. Cardiovasc Interv Ther. 2020 Oct;35(4):393-397. doi: 10.1007/s12928-020-00643-9. Epub 2020 Feb 28. PubMed 32112238 ↗
  • Zeller T, Langhoff R, Rocha-Singh KJ, Jaff MR, Blessing E, Amann-Vesti B, Krzanowski M, Peeters P, Scheinert D, Torsello G, Sixt S, Tepe G; DEFINITIVE AR Investigators. Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study. Circ Cardiovasc Interv. 2017 Sep;10(9):e004848. doi: 10.1161/CIRCINTERVENTIONS.116.004848. PubMed 28916599 ↗
  • Dave RM, Patlola R, Kollmeyer K, Bunch F, Weinstock BS, Dippel E, Jaff MR, Popma J, Weissman N; CELLO Investigators. Excimer laser recanalization of femoropopliteal lesions and 1-year patency: results of the CELLO registry. J Endovasc Ther. 2009 Dec;16(6):665-75. doi: 10.1583/09-2781.1. PubMed 19995111 ↗
  • Roberts D, Niazi K, Miller W, Krishnan P, Gammon R, Schreiber T, Shammas NW, Clair D; DEFINITIVE Ca(+)(+) Investigators. Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: final results of the DEFINITIVE Ca(+)(+) trial. Catheter Cardiovasc Interv. 2014 Aug 1;84(2):236-44. doi: 10.1002/ccd.25384. Epub 2014 Feb 5. PubMed 24402764 ↗
  • Iida O, Urasawa K, Shibata Y, Yamamoto Y, Ando H, Fujihara M, Nakama T, Miyashita Y, Mori S, Diaz-Cartelle J, Soga Y. Clinical Safety and Efficacy of Rotational Atherectomy in Japanese Patients with Peripheral Arterial Disease Presenting Femoropopliteal Lesions: The J-SUPREME and J-SUPREME II Trials. J Endovasc Ther. 2022 Apr;29(2):240-247. doi: 10.1177/15266028211045700. Epub 2021 Sep 13. PubMed 34510954 ↗
  • Shammas NW, Lam R, Mustapha J, Ellichman J, Aggarwala G, Rivera E, Niazi K, Balar N. Comparison of orbital atherectomy plus balloon angioplasty vs. balloon angioplasty alone in patients with critical limb ischemia: results of the CALCIUM 360 randomized pilot trial. J Endovasc Ther. 2012 Aug;19(4):480-8. doi: 10.1583/JEVT-12-3815MR.1. PubMed 22891826 ↗
  • Shammas NW, Shammas GA, Jones-Miller S, Shammas WJ, Bou-Dargham B, Shammas AN, Banerjee S, Rachwan RJ, Daher GE. Long-term outcomes with Jetstream atherectomy with or without drug coated balloons in treating femoropopliteal arteries: A single center experience (JET-SCE). Cardiovasc Revasc Med. 2018 Oct;19(7 Pt A):771-777. doi: 10.1016/j.carrev.2018.02.003. Epub 2018 Feb 9. PubMed 30420096 ↗
  • Gandini R, Pratesi G, Merolla S, Scaggiante J, Chegai F. A Single-Center Experience With Phoenix Atherectomy System in Patients With Moderate to Heavily Calcified Femoropopliteal Lesions. Cardiovasc Revasc Med. 2020 May;21(5):676-681. doi: 10.1016/j.carrev.2019.08.019. Epub 2019 Aug 23. PubMed 31488361 ↗
  • Burckenmeyer F, Aschenbach R, Diamantis I, Teichgraber U. Excimer laser atherectomy in complex peripheral artery disease: a prospective European registry. J Cardiovasc Surg (Torino). 2021 Apr;62(2):153-161. doi: 10.23736/S0021-9509.21.11569-1. Epub 2021 Jan 22. PubMed 33480520 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 26 months is close to that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2023
First posted
Jun 23, 2023
StartActual
Oct 29, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (1 now withdrawn, 1 now active, not recruiting)
Show 2 sites
  • St. Helena Hospital · St. Helena, United StatesRecruiting→Withdrawn
  • Vascular Breakthroughs · Leominster, United StatesRecruiting→Active, not recruiting
Nov 5, 2026
Site contacts
Changed at 12 sites. See the sites
Show 12 sites
  • St. Helena Hospital · St. Helena, United StatesContact removed D•••@ah.orgContact removed S•••@ah.orgContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • Tallahassee Research Institute · Tallahassee, United StatesContact person changed (no phone or email listed)Contact removed (no phone or email listed)
  • The Vascular Care Group · Portland, United StatesContact removed e•••@vascularbreakthroughs.com · •••8838
  • Southcoast Hospitals/Charlton Memorial Hospital · Fall River, United StatesContact removed t•••@southcoast.org
  • Vascular Breakthroughs · Leominster, United StatesContact removed m•••@vascularbreakthroughs.com · •••7860Contact removed e•••@vascularbreakthroughs.com · •••7860Contact removed (no phone or email listed)Contact removed (no phone or email listed)Contact removed (no phone or email listed)
  • Henry Ford Hospital · Detroit, United StatesContact s•••@hfhs.org · •••4864→k•••@hfhs.org · •••1057
  • Heart and Vascular Institute of Central Jersey · New Brunswick, United StatesContact S•••@orcaresearchgroup.com · •••1229→j•••@orcaresearchgroup.com · •••4694Contact removed j•••@orcaresearchgroup.com · •••4694
  • New York Presbyterian Hospital/Columbia University Irving Medical Center · New York, United StatesContact a•••@cumc.columbia.edu · •••4102→h•••@cumc.columbia.edu · •••4102
  • Vascular Solutions of North Carolina · Cary, United StatesContact person changed (no phone or email listed)
  • Ascension St. John · Bartlesville, United StatesContact c•••@ascension.org · •••3616→•••3616
  • University of Texas Southwestern Medical Center · Dallas, United StatesContact E•••@utsouthwestern.edu · •••9449→M•••@utsouthwestern.edu · •••0387
  • Sentara Health Research Center · Norfolk, United StatesContact removed s•••@sentara.com
Nov 5, 2026
Sponsor
Collaborators added: Syntropic; collaborators removed: Syntropic Corelab
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    2 sites changed recruiting status (1 now withdrawn, 1 now active, not recruiting)
    Show 2 sites
    • St. Helena Hospital · St. Helena, United StatesRecruiting→Withdrawn
    • Vascular Breakthroughs · Leominster, United StatesRecruiting→Active, not recruiting
    Sponsor Collaborators added: Syntropic; collaborators removed: Syntropic Corelab
    Site contacts Changed at 12 sites. See the sites
    Show 12 sites
    • St. Helena Hospital · St. Helena, United StatesContact removed D•••@ah.orgContact removed S•••@ah.orgContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • Tallahassee Research Institute · Tallahassee, United StatesContact person changed (no phone or email listed)Contact removed (no phone or email listed)
    • The Vascular Care Group · Portland, United StatesContact removed e•••@vascularbreakthroughs.com · •••8838
    • Southcoast Hospitals/Charlton Memorial Hospital · Fall River, United StatesContact removed t•••@southcoast.org
    • Vascular Breakthroughs · Leominster, United StatesContact removed m•••@vascularbreakthroughs.com · •••7860Contact removed e•••@vascularbreakthroughs.com · •••7860Contact removed (no phone or email listed)Contact removed (no phone or email listed)Contact removed (no phone or email listed)
    • Henry Ford Hospital · Detroit, United StatesContact s•••@hfhs.org · •••4864→k•••@hfhs.org · •••1057
    • Heart and Vascular Institute of Central Jersey · New Brunswick, United StatesContact S•••@orcaresearchgroup.com · •••1229→j•••@orcaresearchgroup.com · •••4694Contact removed j•••@orcaresearchgroup.com · •••4694
    • New York Presbyterian Hospital/Columbia University Irving Medical Center · New York, United StatesContact a•••@cumc.columbia.edu · •••4102→h•••@cumc.columbia.edu · •••4102
    • Vascular Solutions of North Carolina · Cary, United StatesContact person changed (no phone or email listed)
    • Ascension St. John · Bartlesville, United StatesContact c•••@ascension.org · •••3616→•••3616
    • University of Texas Southwestern Medical Center · Dallas, United StatesContact E•••@utsouthwestern.edu · •••9449→M•••@utsouthwestern.edu · •••0387
    • Sentara Health Research Center · Norfolk, United StatesContact removed s•••@sentara.com
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05916950
Collaborators
NAMSA, Syntropic
Responsible party
Sponsor
First posted
Jun 23, 2023
Start date
Oct 29, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Danielle Op den Kamp
Contact
Danielle.op.den.kamp@philips.com
+31 (0)6 27218737
Amanda Franey
Contact
amanda.franey@philips.com
763-218-9506
Pradeep Nair, MD
principal investigator · Cardiovascular Institute of the South (CIS)
Elizabeth Genovese, MD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion